Phase 2Terminated
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered With Valganciclovir in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Lymphoid Malignancies or Lymphoproliferative Disorders
- Sponsor
- HemaQuest Pharmaceuticals Inc. (Industry)
- Enrollment
- 1 enrolled
- Conditions
- Lymphoid Malignancies; Lymphoproliferative Disorders
- Interventions
- HQK-1004; Valganciclovir (may substitute with ganciclovir)
- Ages
- children, adults, older adults
- Registry
- NCT00992732
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to determine if treatment with HQK-1004 and valganciclovir will result in complete or partial responses in patients with EBV-positive lymphoid malignancies or lymphoproliferative disorders.
Primary outcomes
- Overall response rate
History
Last registry update
Primary completion
Started
Registered